NCT03762447 is a Phase 1 clinical trial of INCB086550 in Solid Tumors, sponsored by Incyte Corporation.

Who is sponsoring NCT03762447?

NCT03762447 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03762447?

Interventions in NCT03762447: INCB086550.

What condition does NCT03762447 study?

NCT03762447 studies Solid Tumors.

Is NCT03762447 still recruiting?

NCT03762447 is currently completed. Last updated 11 August 2025.

Last reviewed 2025-08-11 · How we verify

NCT03762447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Completed Phase 1 Last updated 11 August 2025

What this trial tests

Phase 1 trial testing INCB086550 in Solid Tumors in 138 participants. Completed in 17 November 2023.

Timeline

10 December 2018

Primary endpoint
17 November 2023

17 November 2023

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	138
Start date	10 December 2018
Primary completion	17 November 2023
Estimated completion	17 November 2023
Sites	25 locations across France, Italy, Belgium, United Kingdom, United States

Drugs / interventions tested

INCB086550 — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, et al · · 2022 · cited 86× · PMID 35254416 · DOI 10.1158/2159-8290.cd-21-1156
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.
Sasikumar PG, Ramachandra M. · · 2022 · cited 50× · PMID 35585982 · DOI 10.3389/fimmu.2022.752065
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy.
Zhang Y, Wu J, Zhao C, Zhang S, et al · · 2023 · cited 21× · PMID 37056391 · DOI 10.7150/jca.81899
Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers.
Gómez-Sacristán P, Simeon S, Tran-Nguyen VK, Patil S, et al · · 2025 · cited 13× · PMID 38280715 · DOI 10.1016/j.jare.2024.01.024
Development of small molecule drugs targeting immune checkpoints.
Chen L, Zhao X, Liu X, Ouyang Y, et al · · 2024 · cited 10× · PMID 38727005 · DOI 10.20892/j.issn.2095-3941.2024.0034
Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
Patil SP, Fattakhova E, Hofer J, Oravic M, et al · · 2022 · cited 10× · PMID 35631439 · DOI 10.3390/ph15050613
Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint.
Gu T, Tian X, Wang Y, Yang W, et al · · 2023 · cited 5× · PMID 37205112 · DOI 10.3389/fimmu.2023.1145028

Verify or expand the search:

Other trials of INCB086550

Trials testing the same drug.

NCT05101369 — A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550 · Phase 1 · completed
NCT04629339 — Study of INCB086550 in Select Solid Tumors · Phase 2 · terminated
NCT04674748 — To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 · Phase 1 · terminated

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03762447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 11 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing